Key Takeaways | SEC’s Continued Focus on FDA-related Disclosures: What Life Sciences Companies Should Know

Recent SEC enforcement actions make clear that risk remains high for life sciences companies – particularly for public companies and individual executives navigating the FDA approval process. As the Enforcement Division regains momentum heading into 2026, companies in highly regulated sectors should expect a selective but high-impact enforcement approach.

This webinar provided a practical, forward-looking analysis of where SEC enforcement is heading and what it means for life sciences companies.

Key takeaways included:

1. SEC continues to scrutinize FDA-related disclosures of life sciences companies. Even if enforcement priorities shift at the margins, the SEC continues to focus on drug and device development, including disclosures about clinical trials, FDA interactions, manufacturing readiness, and approval prospects. That scrutiny extends beyond SEC filings to earnings calls, investor presentations, scientific publications, and conference statements.
2. Companies face the greatest risk when they create an overly optimistic picture while omitting important FDA concerns. There is generally no duty to disclose every FDA communication, but once a company chooses to speak about regulatory progress, trial results, or approval likelihood, it must avoid half-truths that leave investors with a materially misleading impression.
3. The FDA’s increasing transparency, including real-time publication of complete response letters (CRLs), makes careful disclosure even more important. FDA feedback may now become public much faster than in the past and inconsistencies between company statements and FDA positions are more likely to draw SEC and private-plaintiff attention.
4. Life sciences companies should revisit internal disclosure controls, cross-functional communication, and insider trading safeguards. Potential practical steps include ensuring that FDA-facing scientific and regulatory personnel are aligned with executives and disclosure teams, documenting materiality and disclosure decisions, training key individuals on risks outside formal SEC filings, and carefully monitoring trading windows and other compliance pressure points around significant FDA developments.